FindTrial
Sign In

Prospective determination of perioperative Risk of pancreatioduodenectomy after neoadjuvant stereotactic radiotherapy of pancreatic cancer

Prospective determination of perioperative Risk of pancreatioduodenectomy after neoadjuvant stereotactic radiotherapy of pancreatic cancer - NeoRad

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00019011
Enrollment
22
Registered
2019-12-03
Start date
2020-01-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25.0

Interventions

Group 1: 5 fractions of radiotherapy 3-5 days prior to pancreas resection.

Sponsors

Universitätsklinikum Freiburg, Departemnt Chirurgie, Klinik für Allgemein- und Viszeralchirurgie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with histologically proven resectable ductal adenocarcinoma and ability to give written informed consent

Exclusion criteria

Exclusion criteria: Participation in trial interfering with the trial Infiltration of stomach or intestine Pregnancy and breast feeding Risk of incompliance Unwillingness or inability to perform birth control Bilirubin > 2.5 x upper reference value Clinically relevant duodenal stenosis renal insufficiency with GRF<30

Design outcomes

Primary

MeasureTime frame
Rate of severe complications within 6 weeks after radiotherapy and surgery—

Secondary

MeasureTime frame
30 day mortality—

Countries

Germany

Contacts

Public ContactEleni Gkika

Universitätsklinikum FreiburgKlinik für Strahlenheilkunde

eleni.gkika@uniklinik-freiburg.de+49 (0) 761 270-95200

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026